We’re delighted to announce the appointment of former Touch Bionics CEO, Stuart Mead, as our non-executive Chairman. Stuart comes to the company with a wealth of experience in the leadership of innovative medical devices and prosthetics companies.
Touch Bionics was the developer of the world’s first bionic hand. Stuart led the company from a pre-revenue IP-based business to being one of the leading brands in its field, recognised globally for both innovation and product excellence. Touch Bionics was sold to Icelandic orthotic and prosthetic manufacturer Össur in 2016.
“We are delighted to welcome Stuart to the Adapttech team,” said Peter Dines, COO and Head of Life Sciences & Biosciences at our lead investor, Mercia Asset Management. “As the company moves into its commercialization phase, we wanted to find a business leader with specific expertise in the prosthetics sector, and there are very few people in the world who are as well-qualified as Stuart for this role.”
Stuart has more than 30 years’ experience in technology industries and is experienced in sales and marketing. In addition to Touch Bionics, he has also been CEO of 3D scanning firm Fuel3D and biopharmaceuticals manufacturer Excell Biotech, and held senior management positions at both Kodak Clinical Diagnostics and Johnson & Johnson.
“I’m thrilled to have the opportunity to help Adapttech take its innovative technology to market,” said Stuart Mead, our non-exec Chairman. “We’ve got a big year ahead with our full commercial launch in the United States planned for the third quarter, and I’m looking forward to the challenge.”